FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134924141> ?p ?o ?g. }

• W2134924141 endingPage "2147" @default.
• W2134924141 startingPage "2147" @default.
• W2134924141 abstract "The occurrence of new-onset migraine attacks is a complication of transcatheter atrial septal defect (ASD) closure. It has been suggested that clopidogrel may reduce migraine attacks after ASD closure.To assess the efficacy of clopidogrel, used in addition to taking aspirin, for the prevention of migraine attacks following ASD closure.Randomized, double-blind clinical trial performed in 6 university hospitals in Canada. Participants were 171 patients with an indication for ASD closure and no history of migraine.Patients were randomized (1:1) to receive dual antiplatelet therapy (aspirin + clopidogrel [the clopidogrel group], n = 84) vs single antiplatelet therapy (aspirin + placebo [the placebo group], n = 87) for 3 months following transcatheter ASD closure. The first patient was enrolled in December 2008, and the last follow-up was completed in February 2015.The primary efficacy outcome was the monthly number of migraine days within the 3 months following ASD closure in the entire study population. The incidence and severity of new-onset migraine attacks, as evaluated by the Migraine Disability Assessment questionnaire, were prespecified secondary end points. A zero-inflated Poisson regression model was used for data analysis.The mean (SD) age of the participants was 49 (15) years and 62% (106) were women. Patients in the clopidogrel group had a reduced mean (SD) number of monthly migraine days within the 3 months following the procedure (0.4 [95% CI, 0.07 to 0.69] days) vs the placebo group (1.4 [95% CI, 0.54 to 2.26] days; difference, -1.02 days [95% CI, -1.94 to -0.10 days]; incident risk ratio [IRR], 0.61 [95% CI, 0.41 to 0.91]; P = .04) and a lower incidence of migraine attacks following ASD closure (9.5% for the clopidogrel group vs 21.8% for the placebo group; difference, -12.3% [95% CI, -23% to -1.6%]; odds ratio [OR], 0.38 [95% CI, 0.15 to 0.89]; P = .03). Among patients with migraines, those in the clopidogrel group had less-severe migraine attacks (zero patients with moderately or severely disabling migraine attacks vs 37% [7 patients] in the placebo group; difference, -36.8% [95% CI, -58.5% to -15.2%]; P = .046). There were no between-group differences in the rate of patients with at least 1 adverse event (16.7% [14 patients] in the clopidogrel group vs 21.8% [19 patients] in the placebo group; difference, -5.2% [95% CI, -17% to 6.6%]; P = .44).Among patients who underwent transcatheter ASD closure, the use of clopidogrel and aspirin, compared with aspirin alone, resulted in a lower monthly frequency of migraine attacks over 3 months. Further studies are needed to assess generalizability and durability of this effect.clinicaltrials.gov Identifier: NCT00799045." @default.
• W2134924141 created "2016-06-24" @default.
• W2134924141 creator A5000026084 @default.
• W2134924141 creator A5008815442 @default.
• W2134924141 creator A5012456201 @default.
• W2134924141 creator A5021133301 @default.
• W2134924141 creator A5026732894 @default.
• W2134924141 creator A5032295260 @default.
• W2134924141 creator A5046485954 @default.
• W2134924141 creator A5052765446 @default.
• W2134924141 creator A5053217997 @default.
• W2134924141 creator A5059339083 @default.
• W2134924141 creator A5084407813 @default.
• W2134924141 creator A5088056147 @default.
• W2134924141 date "2015-11-24" @default.
• W2134924141 modified "2023-10-17" @default.
• W2134924141 title "Effect of Clopidogrel and Aspirin vs Aspirin Alone on Migraine Headaches After Transcatheter Atrial Septal Defect Closure" @default.
• W2134924141 cites W1859495753 @default.
• W2134924141 cites W1968425289 @default.
• W2134924141 cites W1971349502 @default.
• W2134924141 cites W1976260818 @default.
• W2134924141 cites W1980382038 @default.
• W2134924141 cites W1985693298 @default.
• W2134924141 cites W2003941801 @default.
• W2134924141 cites W2005010394 @default.
• W2134924141 cites W2010095901 @default.
• W2134924141 cites W2014706503 @default.
• W2134924141 cites W2018584311 @default.
• W2134924141 cites W2027932039 @default.
• W2134924141 cites W2032666115 @default.
• W2134924141 cites W2039224210 @default.
• W2134924141 cites W2053322270 @default.
• W2134924141 cites W2056235558 @default.
• W2134924141 cites W2069789311 @default.
• W2134924141 cites W2077640446 @default.
• W2134924141 cites W2078561853 @default.
• W2134924141 cites W2080053222 @default.
• W2134924141 cites W2092711678 @default.
• W2134924141 cites W2102459986 @default.
• W2134924141 cites W2102481983 @default.
• W2134924141 cites W2111726360 @default.
• W2134924141 cites W2112468109 @default.
• W2134924141 cites W2113860377 @default.
• W2134924141 cites W2136375758 @default.
• W2134924141 cites W2138281777 @default.
• W2134924141 cites W2163973338 @default.
• W2134924141 cites W2166519561 @default.
• W2134924141 cites W2168439673 @default.
• W2134924141 cites W2259429130 @default.
• W2134924141 cites W2418872975 @default.
• W2134924141 cites W2553521302 @default.
• W2134924141 cites W3022454656 @default.
• W2134924141 cites W628914316 @default.
• W2134924141 doi "https://doi.org/10.1001/jama.2015.13919" @default.
• W2134924141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26551304" @default.
• W2134924141 hasPublicationYear "2015" @default.
• W2134924141 type Work @default.
• W2134924141 sameAs 2134924141 @default.
• W2134924141 citedByCount "45" @default.
• W2134924141 countsByYear W21349241412015 @default.
• W2134924141 countsByYear W21349241412016 @default.
• W2134924141 countsByYear W21349241412017 @default.
• W2134924141 countsByYear W21349241412018 @default.
• W2134924141 countsByYear W21349241412019 @default.
• W2134924141 countsByYear W21349241412020 @default.
• W2134924141 countsByYear W21349241412021 @default.
• W2134924141 countsByYear W21349241412022 @default.
• W2134924141 countsByYear W21349241412023 @default.
• W2134924141 crossrefType "journal-article" @default.
• W2134924141 hasAuthorship W2134924141A5000026084 @default.
• W2134924141 hasAuthorship W2134924141A5008815442 @default.
• W2134924141 hasAuthorship W2134924141A5012456201 @default.
• W2134924141 hasAuthorship W2134924141A5021133301 @default.
• W2134924141 hasAuthorship W2134924141A5026732894 @default.
• W2134924141 hasAuthorship W2134924141A5032295260 @default.
• W2134924141 hasAuthorship W2134924141A5046485954 @default.
• W2134924141 hasAuthorship W2134924141A5052765446 @default.
• W2134924141 hasAuthorship W2134924141A5053217997 @default.
• W2134924141 hasAuthorship W2134924141A5059339083 @default.
• W2134924141 hasAuthorship W2134924141A5084407813 @default.
• W2134924141 hasAuthorship W2134924141A5088056147 @default.
• W2134924141 hasBestOaLocation W21349241411 @default.
• W2134924141 hasConcept C126322002 @default.
• W2134924141 hasConcept C141071460 @default.
• W2134924141 hasConcept C142724271 @default.
• W2134924141 hasConcept C168563851 @default.
• W2134924141 hasConcept C204787440 @default.
• W2134924141 hasConcept C27081682 @default.
• W2134924141 hasConcept C2777628954 @default.
• W2134924141 hasConcept C2777849778 @default.
• W2134924141 hasConcept C2778541695 @default.
• W2134924141 hasConcept C2780966972 @default.
• W2134924141 hasConcept C2908647359 @default.
• W2134924141 hasConcept C42219234 @default.
• W2134924141 hasConcept C71924100 @default.
• W2134924141 hasConcept C99454951 @default.
• W2134924141 hasConceptScore W2134924141C126322002 @default.
• W2134924141 hasConceptScore W2134924141C141071460 @default.

• next